The politics of blood: Ethics, innovation and the regulation of risk

The Politics of Blood: Ethics, Innovation and the Regulation of Risk

Volumn , Issue , 2012, Pages 1-264

  Farrell, Anne Maree ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924457220     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139047968     Document Type: Book

References (501)

1. Abraham, J. and Reed, T., ‘Progress, innovation and regulatory science in drug development: the politics of international standard-setting’, Social Studies of Science, 32 (2002), 337–69.
2. Abraham, J. and Reed, T., ‘Trading risks for markets: the international harmonisation of pharmaceuticals regulation’, Health Risk and Society, 3 (2001), 113–28.
3. Alessandrini, M., ‘Community volunteerism and blood donation: altruism as a lifestyle choice’, Transfusion Medicine Reviews, 21 (2007), 307–16.
4. Allain, J.-P., Bianco, C., Blajchman, M. A., Brecher, M. E., Busch, M., Leiby, D., Lin, L. and Stramer, S., ‘Protecting the blood supply from emerging pathogens: the role of pathogen inactivation’, Transfusion Medicine Reviews, 19 (2005), 110–26.
5. Allain, J.-P., Stramer, S. L., Carneiro-Proietti, A. B. F., Martins, M. L., Lopes da Silva, S. N., Ribeiro, M., Proietti, F. A., and Reesink, H. W., ‘Transfusion-transmitted infectious diseases’, Biologicals, 37 (2009), 71–7.
6. Allsop, J., Jones, K. and Baggott, R., ‘Health consumer groups in the UK: a new social movement?’, Sociology of Health and Illness, 26 (2004), 737–56.
7. Alter, H. J. ‘Pathogen reduction: a precautionary principle paradigm’, Transfusion Medicine Reviews, 22 (2008), 97–102.
8. Alter, H. and Klein, H., ‘The hazards of blood transfusion in historical perspective’, Blood, 112 (2008), 2617–26.
9. American Association of Blood Banks (AABB), America’s Blood Centers (ABC) and American Red Cross (ARC), Joint Statement Before BPAC on Behavior-Based Blood Donors Deferrals in the Era of Nucleic Acid Testing (NAT), 9 March 2006 (www.aabb.org/pressroom/statements/Pages/bpacdefernat030906.aspx).
10. Anderson, J. M., ‘Empowering patients: issues and strategies’, Social Science and Medicine, 43 (1996), 697–705.
11. Anderson, S. A., Yang, H., Gallagher, L. M., O’Callagh, S., Forsheet, R. A., Busch, M. P., McKenna, M. T., Williams, I., Williams, A., Kuehnert, M. J., Stramer, S., Kleinman, S., Epstein, J. and Dayton, A. I., ‘Quantitative estimate of the risks and benei ts of possible alternative blood donor strategies for men who have had sex with men’, Transfusion, 49 (2009), 1102–14.
12. Archard, D., ‘Selling yourself: Titmuss’s argument against a market in blood’, Journal of Ethics, 6 (2002), 87–102.
13. Archer, the Right Honourable Lord Archer of Sandwell QC, Jones, N. and Willetts, J., Independent Public Inquiry Report on NHS Supplied Contaminated Blood and Blood Products(2009).
14. Arrow, K., ‘Gifts and exchanges’, Philosophy and Public Affairs, 4 (1972), 343–62.
15. AuBuchon, J. P., ‘Managing change to improve transfusion safety’, Transfusion, 44 (2004), 1377–83.
16. Ayres, I. and Braithwaite, J., Responsive Regulation: Transcending the Deregulation Debate(Oxford University Press, 1992).
17. Bacqué, R., ‘Douze parlementaires pour juger l’affaire du sang contaminé’, Le Monde, 14/01/99.
18. Baggott, R., Allsop, J. and Jones, K., Speaking for Patients and Carers: Health Consumer Groups and the Policy Process(Basingstoke: Palgrave, 2005).
19. Baldwin, R., Cave, M. and Lodge, M., ‘Introduction: Regulation – the field and the developing agenda’, in Baldwin, R., Cave, M. and Lodge, M. (eds.), The Oxford Handbook of Regulation(Oxford University Press, 2010).
20. Barbara, J., Contreras, M. and Hewitt, P., ‘AIDS: a problem for the transfusion service?’ British Journal of Hospital Medicine, 36 (1986), 178–84.
21. Barbara, J. and Flanagan, P., ‘Blood transfusion risk: protecting against the unknown’, British Medical Journal, 316 (1998), 717–18.
22. Barbot, J., ‘How to build an “active patient”? The work of AIDS associations in France’, Social Science and Medicine, 62 (2006), 538–51.
23. Barnett, A., ‘Blood blunder killed over 100 patients’, The Guardian, 7/11/99.
24. Batty, D., ‘Reid agrees compensation over contaminated blood’, The Guardian, 23/01/04.
25. Bayer, R., ‘Blood and AIDS in America: science, politics and the making of an iatrogenic catastrophe’, in Feldman, E. A. and Bayer, R. (eds.), Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster(New York: Oxford University Press, 1999), pp. 20–58.
26. Bayer, R. and Feldman, E. A., ‘Understanding the blood feuds’, in Feldman, E. A. and Bayer, R (eds.), Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster(New York: Oxford University Press, 1999), pp. 2–16.
27. Beal, R., ‘Titmuss revisited’, Transfusion Medicine, 9 (1999), 352–9.
28. Beal, R. and van Aken, W., ‘Gift or good? A contemporary examination of the voluntary and commercial aspects of blood donation’, Vox Sanguinis, 63 (1992), 1–5.
29. Beck, S., ‘Blood centers and plasma centers: mutual benefit’, The Source(Summer 2011), 12–15.
30. Beck, U., Risk Society: Towards a New Modernity(London: Sage, 1992).
31. Berger, K., Klein, H. G., Seitz, R., Schramm, W. and Spieser, J. M., ‘The Wilbad Kreuth initiative: European current practices and recommendations for optimal use of blood components’, Biologicals, 39 (2011), 189–93.
32. Berman, K. E., ‘Expensive blood safety technologies: understanding and managing cost and access-to-care issues’, Transfusion Medicine Reviews, 18 (2004), 1–10.
33. Berner, B., ‘The making of a risk object: AIDS, gay citizenship and the meaning of blood donation in Sweden in the early 1980s’, Sociology of Health and Illness, 33 (2011), 384–98.
34. Berridge, V., ‘AIDS and the gift relationship in the UK’, in Oakley, A. and Ashton, J. (eds.), R. M. Titmuss, The Gift Relationship: From Human Blood to Social Policy(London: LSE Books, 1997), pp. 15–40.
35. Berridge, V., AIDS in the UK: The Making of Policy 1981–1994(Oxford University Press, 1996).
36. Betts, J. P., ‘The United Kingdom: national policy’, Pharmaceuticals Policy and Law, 7 (2006), 233–41.
37. Black, J., ‘Constructing and contesting legitimacy and accountability in polycentric regulatory regimes’, Regulation & Governance, 2 (2008), 137–64.
38. Black, J., ‘Decentring regulation: understanding the role of regulation and self-regulation in a “post-regulatory” world’, Current Legal Problems, 54 (2001), 103–47.
39. Black, J., ‘Proceduralizing regulation: part 1’, Oxford Journal of Legal Studies, 20 (2000), 597–614.
40. Black, J., ‘What is regulatory innovation?’ in Black, J., Lodge, M. and Thatcher, M. (eds.), Regulatory Innovation: A Comparative Analysis(Cheltenham: Edward Elgar, 2005), pp. 1–15.
41. Blajchman, M. A., ‘Transfusion medicine – the coming of age of a new specialty’, Transfusion Medicine Reviews, 1 (1987), 1–3.
42. Blajchman, M. A. and Klein, H. G., ‘Looking back in anger: retrospection in the face of a paradigm shift’, Transfusion Medicine Reviews, 11 (1) (1997), 1–5.
43. Block, F., ‘Introduction’, in Block, F. (ed.), K. Polanyi, The Great Transformation: The Political and Economic Origins of Our Time, 2nd edn (Boston, MA: Beacon Press, 2001), pp. 1–16.
44. Borrás, S., ‘Legitimate governance of risk at the EU level? The case of genetically modified organisms’, Technological Forecasting and Social Change, 73 (2006), 61–75.
45. Borzini, P., Nembri, P. and Biffoni, F., ‘The evolution of transfusion medicine as a stand alone discipline’, Transfusion Medicine Reviews, 11 (1997), 200–8.
46. Boseley, S., ‘Increased offer for NHS patients infected with hepatitis C “disappointing”’, The Guardian, 10/1/11.
47. Boseley, S., ‘NHS imports all plasma to avoid risk of CJD’, The Guardian, 14/5/1998.
48. Bove, L. L., Bednall, T., Masser, B. and Buzza, M., ‘Understanding the plasmapheresis donor in a voluntary, nonremunerated environment’, Transfusion51 (2011) 2411–24.
49. Bovens, M., Hart, P. and Peters, B. G. (eds.), Success and Failure in Public Governance: A Comparative Analysis(Cheltenham: Edward Elgar, 2001).
50. Brahams, D., ‘Trial and tribulations of J-P. Allain’, Lancet, 342 (1993), 232–3.
51. Braithwaite, J., ‘Neoliberalism and regulatory capitalism’, Occasional Paper No. 5, Regulatory Institutions Network(Canberra: ANU, 2005), pp. 1–43.
52. Braithwaite, J., Restorative Justice and Responsive Regulation(Oxford University Press, 2002).
53. Brown, C., ‘£19 million for victims of HIV blood’, The Independent, 24/11/89.
54. Brown, P. and Zavestoski, S., ‘Social movements in health: an introduction’, Sociology of Health and Illness, 26 (2004), 679–94.
55. Brown, P. and Zavestoski, S., Social Movements in Health(Blackwood, NJ: Blackwell Publishing, 2005)
56. Brown, P., Zavestoski, S., McCornick, S., Mayer, B., Morello-Frosch, R. and Gasior Altman, R., ‘Embodied health movements: new approaches to social movements in health’, Sociology of Health and Illness, 26 (2004), 50–80.
57. Brownsword, R., Rights, Regulation, and the Technological Revolution(Oxford University Press, 2008).
58. Brunsson, N. and Jacobsson, B., ‘The contemporary expansion of standardization’, in Brunsson, N., Jacobsson, B. and Associates (eds.), A World of Standards(Oxford University Press, 2000), pp. 1–17.
59. Bult, J. M., ‘Future trends’, Pharmaceuticals Policy and Law, 7 (2006), 263–9.
60. Burnouf, T., ‘Modern plasma fractionation’, Transfusion Medicine Reviews, 21 (2007), 101–17.
61. Burnouf, T., ‘Plasma proteins: Unique biopharmaceuticals – unique economics’, Pharmaceuticals Policy and Law, 7 (2006), 209–18.
62. Busby, H., ‘Biobanks, bioethics and concepts of donated blood in the UK’, Sociology of Health and Illness, 28 (2006), 850–65.
63. Busby, H., ‘The meanings of consent to the donation of cord blood stem cells: perspectives from an interview-based study of a public cord blood bank in England’, Clinical Ethics, 5 (2010), 22–7.
64. Busby, H., ‘Trust, nostalgia and narrative accounts of blood banking in England in the 21st century’, Health, 14 (2010), 369–82.
65. Busch, M. and Custer, B., ‘Health outcomes research using large donorrecipient databases: a new frontier for assessing transfusion safety and contributing to public health’, Vox Sanguinis, 91 (2006), 282–4.
66. Busch, M., Walderhaug, M., Custer, B., Allain, J.-P., Reddy, R. and McDonough, B., ‘Risk assessment and cost-effectiveness/utility analysis’, Biologicals, 37 (2009), 78–87.
67. Byrne, L., Brant, L. J., Davison, K. and Hewitt, P., ‘Transfusion-transmitted human immunodei ciency virus (HIV) from seroconverting donors is rare in England and Wales: results from HIV lookback, October 1995 through December 2008’, Transfusion, 51 (2011), 1339–45.
68. Callum, J. L., Lon, Y., Lima, A. and Merkley, L., ‘Transitioning from “blood” safety to “transfusion” safety: addressing the single biggest risk of transfusion’, ISBT Science Series, 6 (2011), 96–104.
69. Camporesi, P., The Juice of Life: The Symbolic and Magic Signii cance of Blood, trans. R. R. Barr (New York: Continuum Publications, 1996).
70. Cash, J., ‘The blood transfusion service and the National Health Service’, British Medical Journal, 295 (1987), 617–19.
71. Casteret, A. M., L’Affaire du sang contaminé(Paris: Éditions La Decouverte, 1992).
72. Centers for Disease Control, Morbidity and Mortality Weekly Report, July 16, 1982.
73. Centers for Disease Control, Morbidity and Mortality Weekly Report, December 10, 1982.
74. Cervia, J. S., Sowemimo-Coker, S. O., Ortolano, G. O., Wilkins, K., Schaffer, S. and Wortham, S. T., ‘An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob Disease’, Transfusion Medicine Reviews, 20 (2006), 190–206.
75. Cheingsong-Popov, R., Weiss, R., Dalgleish, R. A., Tedder, R. S., Shanson, D. C., Jeffries, D. J., Ferns, R. B., Briggs, E. M., Weller, I. V. and Mitton, S. et al., ‘Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain’, Lancet, ii (1984), 477–80.
76. Chotray, V. and Stoker, G., Governance Theory: A Cross-Disciplinary Approach(Basingstoke: Palgrave Macmillan, 2008).
77. Claxton, K. and Culyer, A. J., ‘Wickedness or folly? The ethics of NICE’s decisions’, Journal of Medical Ethics, 32 (2006), 373–7.
78. Colombani, J.-M., ‘Pourune justice équitable’, Le Monde, 9/02/99.
79. Commission of the European Communities, Communication on Blood Safety and Self-Sufficiency in the Community, COM (94) 652 final, 21.12. 1994.
80. Commission of the European Communities, Communication from the Commission on the Precautionary Principle, COM (2000) 1 final, 2.2. 2000.
81. Commission of the European Communities, European Governance: A White Paper(2001) 428 final, 25.7.2001.
82. Commission of the European Communities, Implementing the Community Lisbon Programme: Communication from the Commission to the Council, the European Parliament, the European Social and Economic Council and the Committee of the Regions, More Research and Innovation – Investing for Growth and Employment: A Common Approach, COM (2005) 488 final, 12.10.2005.
83. Commission of the European Communities, Innovation Tomorrow: Innovation Policy and the Regulatory Framework (Brussels: DG Enterprise, 2002).
84. Commission of the European Communities, Meeting of the competent authorities on blood and blood components: summary report – 13 September 2006 (Art. 25 Dir.2002/98/EC): Brussels SANCO C/6 TB/ges D (2006) 360346.
85. Commission of the European Communities, Proposal for a Directive of the European Parliament and of the Council setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Council Directive 89/381/EEC, COM (2000) 816 final, 13.12.2000.
86. Commission of the European Communities, Report on the promotion by Member States of voluntary unpaid blood donations. Report from the Commission to the Council and the European Parliament on the promotion by Member States of voluntary, unpaid blood donations, COM (2006) 217 final, 17.5.2006.
87. Commission of the European Communities, Report from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions: First Report on the Application of the Blood Directive COM (2006) 313 final, 19.6.2006, Brussels.
88. Confidentiality Arrangements concluded between the EU (EC and EMEA) and the US (FDA/DHHS), Implementation Plan for Medicinal Products for Human Use (updated June 2007) (www.emea.europa.eu/docs/en_GB/document_library/Other/2009/12/WC500017981.pdf).
89. Cooper, M. H. and Culyer, A. J., The Price of Blood(London: Institute of Economic Affairs, 1968).
90. Corkin, J., ‘Science, legitimacy and the law: regulating risk regulation judiciously in the European Community’, European Law Review, 33 (2008), 359–84.
91. Council Conclusions of 13 December 1993 on self-sufficiency in blood in the European Community, OJC 15, 18.1.1994.
92. Council of Europe, European Directorate for the Quality of Medicines and HealthCare (EDQM) (www.edqm.eu).
93. Council of Europe, European Directorate for the Quality of Medicines and Health Care, Guide to the Preparation, Use and Quality Assurance of Blood Components, 16th edn (Strasbourg: Council of Europe, 2010) (www.edqm.eu).
94. Council of Europe, European Directorate for the Quality of Medicines and HealthCare, Pharmacopoeial Discussion Group. International Harmonisation: Statement of Harmonisation Policy (2003) (www.edqm.eu).
95. Council of Europe, European Directorate for the Quality of Medicines and HealthCare, Terms of Reference of the European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS) Factsheet, 1076th Meeting, (3–4 February 2010) (www.edqm.eu).
96. Council of Europe, European Directorate for the Quality of Medicines and HealthCare, Working Procedures of the Pharmacopoeial Discussion Group (PDG), Revised Version (June 2010) (www.edqm.eu).
97. Council Resolution of 2 June 1995 on blood safety and self-sufficiency in the Community, OJC 164, 30.6.1995.
98. Council Resolution of 11 December 1996 on a strategy towards blood safety and self-sufficiency in the European Community, OJ C 374, 11.12.1996.
99. Custer, B., ‘Economic analyses of blood safety and transfusion medicine interventions: a systematic review’, Transfusion Medicine Reviews, 18 (2004), 127–43.
100. Custer, B., Agapova, M. and Havlir Martinez, R., ‘The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model’, Transfusion, 50 (2010), 2461–73.
101. Custer, B. and Hoch, J. S., ‘Cost-effectiveness analysis: what it really means for transfusion medicine decision making’, Transfusion Medicine Reviews, 23 (2009), 1–12.
102. Davies, S. C., ‘Editorial: Reforming England’s blood transfusion service’, British Medical Journal, 311 (1995), 1383–4.
103. Davis, C. and Abraham, J., ‘Rethinking innovation accounting in pharmaceutical regulation: a case study in the deconstruction of therapeutic advance and therapeutic breakthrough’, Science, Technology and Human Values, 36 (2011), 791–815.
104. Davis, R. E., Vincent, C. A. and Murphy, M. F., ‘Blood transfusion safety: the potential role of the patient’, Transfusion Medicine Reviews, 25 (2011), 12–23.
105. Davison, J. and Driscoll, M., ‘Compensation fight delayed by secrecy’, The Sunday Times, 29/7/90.
106. Davison, J. and Driscoll, M., ‘Doctors back haemophiliacs’, The Sunday Times, 11/11/90.
107. Davison, K. L., Brant, L. J., Presanis, A. M. and Soldan, K., ‘A re-evaluation of the risk of transfusion-transmitted HIV prevented by the exclusion of men who have sex with men from blood donation in England and Wales, 2005–2007’, Vox Sanguinis101 (2011) 291–302.
108. de Búrca, G. and Scott, J., ‘Introduction: new governance, law and constitutionalism’, in de Búrca, G. and Scott, J. (eds.), Law and New Governance in the EU and the US(Oxford: Hart Publishing, 2006), pp. 1–14.
109. Delacourt, J., ‘European Court of Justice weighs in on donor compensation debate’, The Source(Summer 2011), 16–17.
110. del Pozo, P. R., ‘Paying donors and the ethics of blood supply’, Journal of Medical Ethics, 20 (1994), 31–5.
111. de Sadeleer, N., ‘The precautionary principle in EC environmental and health law’, European Law Journal, 12 (2006), 139–72.
112. Department of Health, Government response to Lord Archer’s independent report on NHS supplied contaminated blood and blood products (London: Department of Health, 2009).
113. Department of Health, Lifetime blood donation ban lifted for men who have had sex with men, Press Release – 8 September 2011 (http://mediacentre.dh.gov.uk).
114. Devine, K., ‘Risky business? The risks and benefits of umbilical cord blood collection’, Medical Law Review, 18 (2010), 330–62.
115. Dickenson, D., ‘Consent, commodification and benefit-sharing in genetic research’, Developing World Bioethics, 4 (2004), 109–24.
116. Djelic, M.-L. and Quack, S., ‘Transnational communities and governance’, in Djelic, M.-L. and Quack, S. (eds.), Transnational Communities: Shaping Global Economic Governance(Cambridge University Press, 2009), pp. 3–36.
117. Djelic, M.-L. and Sahlin-Andersson, K., ‘Introduction: A world of governance: the rise of transnational regulation’, in Djelic, M.-L. and Sahlin-Andersson, K. (eds.), Transnational Governance: Institutional Dynamics of Regulation(Cambridge University Press, 2006), pp. 1–28.
118. Dodd, R., ‘Editorial: Prions and precautions: be careful for what you ask’, Transfusion, 50 (2010), 956–8.
119. Dodd, R., Roth, W. K., Ashford, P., Dax, E. M. and Vyas, G., ‘Transfusion medicine and safety’, Biologicals, 37 (2009), 62–70.
120. Domen, R. E., ‘Paid-versus-volunteer blood donation in the United States: a historical overview’, Transfusion Medicine Reviews, 10 (1995), 53–9.
121. Dorozynski, A., ‘French doctors face second trial’, British Medical Journal, 309 (1994), 427.
122. Douglas, H., Science, Policy and the Value-Free Ideal(University of Pittsburgh Press, 2009).
123. Douglas, M., ‘Foreword: No free gifts’, in Mauss, M., The Gift: The Form and Reason for Exchange in Archaic Societies(London: Routledge, 1990), translated by W. D. Halls from M. Mauss, ‘Essai sur le don’, Sociologie et Anthropologie (Paris: Presses Universitaires de France, 1950), pp. vii–xviii.
124. Douglas, M., Risk Acceptability According to the Social Sciences(London: Routledge, 1985).
125. Douglas, M., Risk and Blame(London: Routledge, 1992).
126. Drake, A. W., Finkelstein, S. N. and Sapolsky, H. M., The American Blood Supply(Cambridge, MA: MIT Press, 1982).
127. Driscoll, M., ‘200 MPs join compensation battle’, The Sunday Times, 5/11/89.
128. Dyer, C., ‘Clarke urged to settle AIDS claims’, The Guardian, 3/08/90.
129. Dyer, C., ‘Judge urges haemophilia settlement’, The Guardian, 1/10/90.
130. Dzik, S., Aubuchon, J., Jeffries, L., Kleinman, S., Manno, C., Murphy, M. F., Popovsky, M. A., Sayers, M., Silberstein, L. E., Slichter, S. J. and Vamvakas, E. C., ‘Leukocyte reduction of blood components: public policy and new technology’, Transfusion Medicine Reviews, 14 (2000), 34–52.
131. Ebner, A., ‘Transnational markets and the Polanyi problem’, in Joerges, C. and Falke, J. (eds.), Karl Polanyi, Globalisation and the Potential of Law in Transnational Markets(Oxford: Hart Publishing, 2011), pp. 19–40.
132. Eder, A., Goldman, M., Rossmann, S., Waxman, D. and Bianco, C., ‘Selection criteria to protect the blood donor in North America and Europe: past (dogma), present (evidence) and future (hemovigilance)’, Transfusion Medicine Reviews, 23 (2009), 205–20.
133. Eder, A. F. and Menitove, J. E., ‘Blood donations past, present and future’, Transfusion, 50 (2010), 1870–7.
134. Editorial, ‘The national blood transfusion service today’, British Medical Journal, 281 (1980), 405–6.
135. Editorial, ‘Blood transfusion, haemophilia and AIDS’, Lancet, ii (1984), 1433–5.
136. Editorial, ‘Palais d’injustice’, Lancet, 342 (1993), 188.
137. Elliot, C., French Criminal Law(Devon: Willan Publishing, 2001).
138. Emmanuel, E. J., ‘Is health care a commodity?’, Lancet, 350 (1997), 1713–14.
139. Epstein, S., Impure Science: AIDS, Activism and the Politics of Knowledge(Berkeley, CA: University of California Press, 1996).
140. Ertmann, M. M. and Williams, J. (eds.), Rethinking Commodification: Cases and Readings in Law and Culture (New York University Press, 2005).
141. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), Guideline on the Scientific Data Requirements for a Plasma Master File (PMF), EMEA/CPMP/BWP/3704/03, 26 February 2004.
142. European Commission, Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions on the application of Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC, COM (2010) 3 final, 19.1.2010, Brussels.
143. European Commission, Meeting of the Competent Authorities on Blood and Blood Components (Art. 25 Dir. 2002/98/EC), 12–13 April 2010, SANCO C6 TB/RP D(2010) 360180 Brussels.
144. European Commission, Meeting of the Competent Authorities on Blood and Blood Components, Summary Report, 16–17 May 2011, SANCO D4/SV/hp ARES(2011), Brussels.
145. European Commission, Report from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. 2nd Report on Voluntary and Unpaid Donation of Blood and Blood Components. COM (2011) 138 final.
146. European Haemophilia Consortium (EHC) (www.ehc.eu).
147. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Guideline on Epidemiological Data on Blood Transmissible Infections, EMA/CHMP/BWP/548524/2008, 22 April 2010.
148. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Guideline on Plasma-Derived Medicinal Products, EMA/CHMP/BWP/706271/2010, 21 July 2011.
149. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) (www.ema.europa.eu).
150. European Medicines Agency, Plasma Master File (PMF) (www.ema.europa.eu).
151. European Opinion Research Group (EEIG), Le don de sang, Eurobaromètre spécial, 1883–4/Vague 58.2 (Brussels: European Commission, 2003).
152. European Parliament, Resolution on blood safety in the European Union, OJC 249, 25.09.1995.
153. European Parliament, Resolution on the communication from the Commission on blood safety and self-sufficiency in the European Community, OJ C 141, 13.05.1996.
154. European Parliament, Resolution on safe blood transfusions and use of blood derivatives, OJ C 329, 6.12.1993.
155. European Parliament, Resolution on self-sufficiency in and safety of blood and its derivatives in the European Community, OJ C 268, 4.10.1993.
156. Evatt, B. L., ‘The natural evolution of haemophilia care: developing and sustaining comprehensive care globally’, Haemophilia, 12 (2006), 13–21.
157. Everson, M. and Vos, E., ‘The scientii cation of politics and the politicisation of science’, in Everson, M. and Vos, E. (eds.), Uncertain Risks Regulated(London: Routledge-Cavendish, 2009), pp. 1–17.
158. Faber, J.-C., ‘The European Blood Directive: a new era of blood regulation has begun’, Transfusion Medicine, 14 (2004), 257–73.
159. Farrell, A. M., ‘Addressing organ shortage in the European Union: getting the balance right’, in Farrell, A. M., Price, D. and Quigley, M. (eds.), Organ Shortage: Ethics Law and Pragmatism(Cambridge University Press, 2011), pp. 227–44.
160. Farrell, A. M., ‘Is the gift still good? Examining the politics and regulation of blood safety in the European Union’, Medical Law Review, 14 (2006), 155–79.
161. Farrell, A. M., ‘The emergence of EU governance in public health: the case of blood policy and regulation’, in Steffen, M. (ed.), Health Governance in Europe(London: Routledge, 2005), pp. 134–51.
162. Farrell, A. M., ‘The politics of risk and EU governance of human material’, Maastricht Journal of European and Comparative Law, 16 (2009), 41–64.
163. Farrell, A. M. and Brazier, M., ‘Consent to blood transfusion’, British Medical Journal, 341 (2010), c4336.
164. Farrugia, A., ‘International movement of plasma and plasma contracting’, in Vyas, G. N. and Williams, A. E. (eds.), Advances in Transfusion Safety(Basel: Karger, 2005), pp. 85–96.
165. Farrugia, A., ‘Product delivery in the developing world: options, opportunities and threats’, Haemophilia, 10 (2004), 77–82.
166. Farrugia, A., ‘Safety and supply of haemophilia products: worldwide perspectives’, Haemophilia, 10 (2004), 327–33.
167. Farrugia, A., ‘The mantra of blood safety: time for a new tune?’, Vox Sanguinis, 86 (2004), 1–7.
168. Farrugia, A., ‘The regulatory pendulum in transfusion medicine’, Transfusion Medicine Reviews, 16 (2002), 273–82.
169. Farrugia, A., Gustafson, M. and von Hoegen, I., ‘Decades of safety measures’, The Source(Spring 2009), 8–12.
170. Faulkner, A., Medical Technology into Healthcare and Society: A Sociology of Devices, Innovation and Governance(Houndmills: Palgrave Macmillan, 2009).
171. Feldman, E. A., ‘Blood justice: courts, conflict and compensation in Japan, France and the United States’, Law and Society Review, 34 (2000), 651–701.
172. Feldman, E. A. and Bayer, R. (eds.), Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster(New York: Oxford University Press, 1999).
173. Felstiner, W. L. F., Abel, R. L. and Sarat, A., ‘The emergence and transformation of disputes: naming, blaming and claiming…’, Law and Society Review, 15 (1980–81), 631–54.
174. Fidler, D. P. and Gostin, L. O., ‘The new International Health Regulations: an historic development for international law and public health’, Journal of Law, Medicine and Ethics, 34 (2006), 85–94.
175. Fisher, E., ‘Opening Pandora’s box: contextualising the precautionary principle in the European Union’, in Everson, M. and Vos, E. (eds.), Uncertain Risks Regulated(London: Routledge-Cavendish, 2009), pp. 21–45.
176. Everson, M. and Vos, E. Risk Regulation and Administrative Constitutionalism(Oxford: Hart Publishing, 2007).
177. Flanagan, P., ‘ISBT Board response to the Dublin consensus statement’, Vox Sanguinis, 100 (2011), 250–1.
178. Fletcher, M., ‘Haemophiliacs with AIDS to get cash help’, The Times, 11/11/87.
179. Føllesdal, A., ‘Legitimacy theories of the European Union’, ARENA Working Papers, WP 04/15 (2004), 1–38.
180. Food and Drug Administration, Blood Donations from Men Who Have Sex with Other Men Questions and Answers (www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/questionsaboutblood/ucm108186.htm).
181. Food and Drug Administration, Workshop on Behavior-Based Donor Deferrals in the NAT Era, 8 March 2006 (www.fda.gov).
182. Foster, K. R., Vecchia, P. and Repacholi, M. J., ‘Science and the precautionary principle’, Science, 288 (2000), 979–81.
183. Franceschi, S., Dal Maso, L. and La Vecchia, C., ‘Trends in incidence of AIDS associated with transfusion of blood and blood products in Europe and the United States, 1985–93’, British Medical Journal, 311 (1995), 1534–6.
184. Franchini, M. and Lippi, G., ‘Recombinant Factor VIII concentrates’, Seminars in Thrombosis and Hemostasis, 36 (2010), 493–7.
185. Fraser, B., ‘Seeking a safer blood supply’, Lancet, 365 (2005), 559–60.
186. Freeman, C., The Economics of Industrial Innovation(London: Pinter, 1982).
187. Freeman, R., ‘HIV and the blood supply in the United Kingdom: professionalism and pragmatism’, in Bovens, M., Hart, P. and Peters, B. G. (eds.), Success and Failure in Public Governance: A Comparative Analysis(Cheltenham: Edward Elgar, 2001), pp. 567–81.
188. Friedman, M.A., Lead Deputy Commissioner, Food and Drug Administration, Testimony on FDA’s regulation of blood, blood products, and plasma, before the House Committee on Government Reform and Oversight, Subcommittee on Human Resources and Intergovernmental Relations, 5 June 1997 (www.hhs.gov/asl/testify/t970605a.html).
189. Funtowicz, S. O. and Ravetz, J. R., ‘Risk management as a post normal science’, Risk Analysis, 12 (1992), 95–7.
190. Funtowicz, S., Shepherd, I., Wilkinson, D. and Ravetz, J. R., ‘Science and governance in the European Union: a contribution to the debate’, Science and Public Policy, 27 (2000), 327–36.
191. Gabe, J., Kelleher, D. and Williams, G. (eds.), Challenging Medicine(London: Routledge, 1994).
192. Galarneau, C., ‘Blood donation, deferral and discrimination: FDA donor deferral policy for men who have sex with men’, American Journal of Bioethics, 10 (2010), 29–39.
193. Ganchoff, C., ‘Speaking for stem cells: biomedical activism and emerging forms of patienthood’, Advances in Medical Sociology, 10 (2008), 225–45.
194. Garber, K., ‘rFactor VIII dei cit questioned’, Nature Biotechnology, 18 (2000), 1133.
195. Gaul, G., ‘The blood brokers: the loose way the FDA regulates blood industry’, Philadelphia Inquirer, 25/9/89.
196. Gelblat, S., ‘Les victims dénoncent un “procès truqué”’, Le Figaro, 10/03/99.
197. Germain, M., ‘Application of a risk modelling technique to blood donor deferral issues’, in Chiavetta, J. A., Deeks, S., Goldman, M., Hannon, J., Leach-Bennett, J., Megann, H., O´ Brien, S. and Webert, K. (eds.), ‘Proceedings of consensus conference: blood-borne HIV and hepatitis –optimizing the donor selection process’, Transfusion Medicine Reviews, 17 (2003), 1–30 at 6.
198. Germain, M., Remis, R. S. and Delage, G., ‘The risks and benefits of accepting men who have had sex with men as blood donors’, Transfusion, 43 (2003), 25–33.
199. Geronimi, J. P., Henry-Bonnot, F., Feltz, A., Morelle, A., Roquel, A. and Vernerey, M., Les Collectes de sang en milieu pénitentiare(Paris: Inspection Générale des services judiciaires ISGJ RMT 1392 IGAS Code Mission SA07 No. 92 119) (Novembre 1992).
200. Gibb, F., ‘AIDS victims back in Court to urge release of papers’, The Times, 11/09/90.
201. Giddens, A., The Consequences of Modernity(Stanford University Press, 1990).
202. Gieryn, T., ‘Boundary-work and the demarcation of science from non-science: strains and interests in professional ideologies of scientists’, American Sociological Review, 48 (1983), 781–95.
203. Gillespie, T. W. and Hillyer, C. D., ‘Blood donors and factors impacting the blood donation decision’, Transfusion Medicine Reviews, 16 (2002), 115–30.
204. Gold, R., Body Parts: Property Rights and the Ownership of Human Biological Materials(Washington, DC: Georgetown University Press, 1996).
205. Goldberg, R., ‘Paying for bad blood: strict product liability after the Hepatitis C litigation’, Medical Law Review, 10 (2002), 165–200.
206. Goldman, M., Yi, Q.-L., Ye, X., Tessier, L. and O’Brien, S. F., ‘Donor understanding about current and potential deferral criteria for high-risk sexual behavior’, Transfusion51 (2011) 1829–34.
207. Goncalves, M. H., Muon, M. C. and d’Almeida Goncalves, J., ‘Transposition of the blood directive – perspective of Portugal’, Transfusion Clinique et Biologique, 12 (2005), 18–20.
208. Goodrich, R., ‘A balanced approach to blood safety: a possible role for PRT’, in Areya, C., Nakhasi, H., Mied, P., Epstein, J., Hughes, J. Gwinn, M., Kleinman, S., Dodd, R., Stramer, S., Walderhaug, M., Ganz, P., Goodrich, R., Tibbetts, C. and Asher, D., ‘FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety’, Transfusion51 (2011) 1863–4.
209. Gostin, L. O., ‘Meeting the survival needs of the world’s least healthy people: a proposed model for global health governance’, Journal of the American Medical Association, 298 (2007), 225–8.
210. Gottweis, H., Salter, B. and Walby, C., The Global Politics of Human Embryonic Stem Cell Science: Regenerative Medicine in Transition(Houndmills: Palgrave Macmillan, 2009).
211. Graves, N., Clare, G., Haines, M. and Bird, R., ‘A policy case study of blood in Australia’, Social Science and Medicine, 71 (2010), 1677–82.
212. Greilsamer, L., Le proc è s du sang contaminé(Paris: Éditions Le Monde, 1992).
213. Greilsamer, L., ‘Notre carence collective…’, Le Monde, 24/07/92.
214. Grenfell, P., Nutland, W., McManus, S., Datta, J., Soldan, K. and Wellings, K., ‘Views and experiences of men who have sex with men on the ban on blood donation: a cross sectional survey with qualitative interviews’, British Medical Journal, 343 (2011), d5604.
215. Grifols, V., ‘Financing plasma proteins: unique challenges’, Pharmaceuticals Policy and Law, 7 (2006), 187–98.
216. Grin, J. and van de Graaf, H., ‘Technology assessment as learning’, Science, Technology and Human Values, 21 (1996), 72–99.
217. Grippner, G., Granovetter, M., Block, F., Biggart, N., Beamish, T., Hsing, Y., Hart, G., Arrighi, G., Mendell, M., Hall, J., Burawoy, M., Vogel, S. and O’Riain, S., ‘Polanyi symposium: a conversation on embeddedness’, Socio-Economic Review, 2 (2007), 109–35.
218. Guibert, N., ‘La Cour de cassation cl ô t d é i nitivement l’affaire du sang contaminé’, Le Monde, 20/06/2003.
219. Haas, P. M., ‘Introduction: Epistemic communities and international policy coordination’, International Organization, 46 (1992), 1–35.
220. Hagen, P., Blood: Gift or Merchandise? Towards an International Blood Policy(New York: Alan R. Liss Inc., 1982).
221. Hagen, P., Blood Transfusion in Europe: A ‘White Paper’(Strasbourg: Council of Europe, 1993).
222. Hammitt, J. K., Weiner, J. B., Swedlow, B., Kall, D. and Zhou, Z., ‘Precautionary regulation in Europe and the United States: a quantitative comparison’, Risk Analysis, 25 (2005), 1215–28.
223. Harris, J., ‘NICE is not cost-effective’, Journal of Medical Ethics, 32 (2006), 378–80.
224. Havighurst, C. C., ‘Trafficking in human blood: Titmuss (1970) and products liability’, Law and Contemporary Problems, 72 (2009), 1–15.
225. Healy, K., Last Best Gifts: Altruism and the Market for Human Blood and Organs(Chicago University Press, 2006).
226. Hensler, D., Pace, N. M., Dombey-Moore, B., Giddens, B., Gross, J. and Molker, K., ‘Blood clotting products for haemophiliacs: in re Factor VIII or IX Concentrate Blood Products’, in Class Action Dilemmas: Pursuing Public Goals for Private Gain(Rand Corporation Publications, 2000), pp. 293–317.
227. Hergon, E., Moutel, G., Duchange, N., Bellier, L., Rouger, P. and Hervé, C., ‘Risk management in transfusion after the HIV blood contamination crisis in France: the impact of the precautionary principle’, Transfusion Medicine Reviews, 19 (2005), 273–80.
228. Hermitte, M.-A., Le sang et le droit(Paris: Éditions du Seuil, 1996).
229. Hess, D., ‘Technology- and product-oriented movements: approximating social movement studies and science and technology studies’, Science Technology and Human Values, 30 (2005), 515–35.
230. Heyvaert, V., ‘Europe in a climate of risk: three paradigms at play’, LSE Law, Society and Economy Working Papers, 06/2010, 1–27.
231. Hillyer, C. D., Blumberg, N., Glynn, S. A. and Ness, P. M., ‘Transfusion recipient epidemiology and outcomes research: possibilities for the future’, Transfusion, 48 (2008), 1530–7.
232. Home News, ‘£42 million AIDS case finishes’, The Guardian, 11/06/91.
233. Hood, C., Rothstein, H. and Baldwin, R., The Government of Risk: Understanding Risk Regulation Regimes (Oxford University Press, 2001).
234. House of Commons, Parliamentary Debates, Vol. 105, 832–58.
235. House of Commons, Parliamentary Debates, Vol. 122, 767, 16/11/87.
236. House of Commons, Parliamentary Debates (Hansard), Statement by the Honourable Mr Andrew Lansley, Secretary of State for Health, Contaminated Blood, Vol. 521, No. 95, Cols. 33–35, 10/01/2011.
237. House of Commons, Social Services Committee, Problems Associated with AIDS(Paper 192–1), Vol. 1 (London: HMSO, 1987).
238. Howse, R., ‘Democracy, science and free trade: risk regulation on trial at the World Trade Organization’, Michigan Law Review, 98 (2000), 2329–57.
239. Hurley, R., ‘Bad blood: gay men and blood donation’, British Medical Journal, 338 (2009), b779.
240. Hutt, E., ‘Specialised plasma products’, Pharmaceuticals Policy and Law, 7 (2006), 67–73.
241. Hutter, B., ‘The attractions of risk-based regulation: accounting for the emergence of risk ideas in regulation’, CARR Discussion Paper, No. 33 (March 2005), pp. 1–18.
242. INRA Europe, Europeans and Blood, Eurobarometer 41.0(Brussels: European Commission, 1995).
243. International Federation of Blood Donor Organizations (FIODS) (www.fiods.org).
244. International Federation of Red Cross and Red Crescent Societies (IFRC) (www.ifrc.org).
245. International Patient organization for Primary Immunodeficiencies (IPOPI) (www.ipopi.org).
246. International Plasma Fractionation Association (IPFA), IPFA Position Statement: Towards a Safe, Secure and Sufficient and National Supply of Plasma Products. Executive Summary. EB–2009–06.
247. Jacobson, N. M., ‘The art of balanced production’, Pharmaceuticals Policy and Law, 7 (2006), 81–7.
248. Jacobsson, B., ‘Standardization and expert knowledge’, in Brunsson, N., Jacobsson, B. and Associates (eds.), A World of Standards(Oxford University Press, 2000), pp. 40–9.
249. Janowitz, W. R., ‘Safety of the blood supply – liability for transfusion associated AIDS’, Journal of Legal Medicine, 9 (1988), 611–22.
250. Jasanoff, S., ‘Citizens at risk: cultures of modernity in the US and EU’, Science as Culture, 11 (2002), 363–80.
251. Jasanoff, S., Designs on Nature: Science and Democracy in Europe and the United States. (Princeton University Press, 2005).
252. Jasanoff, S., ‘Judgment under siege: the three-body problem of expert legitimacy’, in Maasen, S. and Weingart, P. (eds.), Democratization of Expertise? Exploring Novel Forms of Scientific Advice in Political Decision-Making – Sociology of the Sciences, 24 (2005), 209–24.
253. Jasanoff, S. The Fifth Branch: Science Advisers as Policymakers(Cambridge, MA: Cambridge University Press, 1990).
254. Jasper, J. and Poulsen, J., ‘Recruiting strangers and friends: moral shocks and social networks in animal rights and anti-nuclear protests’, Social Problems, 42 (1995), 104–26.
255. Jevons, F., ‘Who wins from innovation?’ Technology Analysis & Strategic Management, 4 (1992), 399–412.
256. Johnson, D. B., Blood Policy: Issues and Alternatives. Proceedings of a Conference sponsored by the Center for Health Policy Research of the American Enterprise Institute for Public Policy Research (Washington, DC: American Enterprise Institute, 1977).
257. Jones, P., ‘Factor VIII: supply and demand’, British Medical Journal, 280 (1980), 1531–2.
258. Jordana, J. and Levi- Faur, D., ‘The politics of regulation in the age of governance’, in Jordana, J. and Levi-Faur, D. (eds.), The Politics of Regulation: Institutions and Regulatory Reforms for the Age of Governance(Cheltenham: Edward Elgar, 2004), pp. 1–28.
259. Kasperson, R. E., Renn, O., Slovic, P., Brown, H., Emel, J., Goble, R., Kasperson, J. X. and Ratick, S., ‘The social ampliication of risk’, Risk Analysis, 8 (1988), 177–87.
260. Katz, L., ‘Risk modeling in the health care environment: an overview’, in Chiavetta, J. A., Deeks, S., Goldman M. et al. (eds.), ‘Proceedings of consensus conference: blood-borne HIV and hepatitis – optimizing the donor selection process’, Transfusion Medicine Reviews, 17 (2003), 1–30.
261. Keeler, J. and Hall, P., ‘Interest representation and the politics of protest’, in Guyomarch, A., Machin, H., Hall, P. and Hayward, J. (eds.), Developments in French Politics 2(Houndmills: Palgrave, 2001), pp. 50–67.
262. Keeling, D., Tait, C. and Makris, M., ‘Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders’, Haemophilia, 14 (2008), 671–84.
263. Kelleher, D., ‘Self-help groups and medicine’, in Gabe, J., Kelleher, D. and Williams, G. (eds.), Challenging Medicine(London: Routledge, 1994), 104–17.
264. Kelly, J., ‘The liability of blood banks and manufacturers of clotting products to recipients of HIV-infected blood: a comparison of the law and reaction in the United States, Canada, Great Britain, Ireland and Australia’, John Marshall Law Review, 27 (1994), 465–91.
265. Kent, J., Faulkner, A., Geesink, I. and FitzPatrick, D., ‘Towards governance of human tissue engineered technologies in Europe: framing the case for a new regulatory regime’, Technological Forecasting and Social Change, 73 (2006), 41–60.
266. Keohane, R. O., ‘Governance in a partially globalized world’, in Held, D. and McGrew, A. (eds.), Governing Globalization: Power, Authority and Global Governance(Cambridge: Polity Press, 2002), pp. 325–47.
267. Keohane, R. O. and Nye, J. S. Jr, ‘Introduction’, in Nye, J. S. Jr and Donahue, J. D. (eds.), Governing in a Globalizing World(Washington, DC: Brookings Institution, 2000), pp. 1–41.
268. Keown, J., ‘The gift of blood in Europe: an ethical defence of EC Directive 89/381’, Journal of Medical Ethics, 23 (1997), 96–100.
269. Kern, J. M. and Croy, B. B., ‘A review of transfusion-associated AIDS litigation: 1984 through 1993’, Transfusion, 34 (1994), 484–91.
270. Keshavjee, S., Weiser, S. and Kleinman, A., ‘Medicine betrayed: hemophilia patients and HIV in the US’, Social Science and Medicine, 53 (2001), 1081–94.
271. Kielmann, K. and Cataldo, F., ‘Tracking the rise of the “expert patient” in evolving paradigms of HIV care’, AIDS Care, 22 (2010), 21–8.
272. Kincaid, H., Dupré, J. and Wylie, A., Value-Free Science?: Ideas and Illusions(Oxford University Press, 2007).
273. Kingdon, J. W., Agendas, Alternatives and Public Policies, 1st edn (Boston: Little Brown, 1984).
274. Kirp, D., ‘The politics of blood: hemophilia activism in the AIDS crisis’, in Feldman, E. A. and Bayer, R. (eds.), Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster(New York: Oxford University Press, 1999), pp. 293–322.
275. Kitcher, P., Science, Truth and Democracy(Oxford University Press, 2001).
276. Klein, H. G., ‘Transfusion medicine: the evolution of a new discipline’, Journal of the American Medical Association, 258 (1987), 2108–9.
277. Klein, H., ‘Will blood transfusion ever be safe enough?’, Journal of the American Medical Association, 284 (2000), 238–40.
278. Klein, H. G., Spahn, D. R. and Carson, J. L., ‘Red blood cell transfusion in clinical practice’, Lancet, 370 (2007), 415–26.
279. Kohler-Koch, B. and Rittberger, B., ‘The governance turn in EU studies’, Journal of Common Market Studies, 44 (2006), 27–49.
280. Kramer, J., ‘Bad blood’, The New Yorker(11/10/93), 74–95.
281. Krause, K., ‘Integrate blood and plasma collections: a modern approach’, Pharmaceuticals Policy and Law, 7 (2006), 49–54.
282. Kretschmer, V., Weippert-Kretschmer, M., Slonka, J., Karger, R. and Zeiler, T., ‘Perspectives of paid whole and plasma donation’, in Vyas, G. N. and Williams, A. E. (eds.), Advances in Transfusion Safety(Basel: Karger, 2005), pp. 101–11.
283. Krever, the Honourable Mr Justice H., Commission of Inquiry on the Blood System in Canada, 3 vols (Ottawa: Canadian Government Publishing, 1997).
284. Kriebel, D. and Tickner, J., ‘Reenergizing public health through precaution’, American Journal of Public Health, 91 (2001), 1351–55.
285. Krimsky, S. and Golding, D. (eds.), Social Theories of Risk(Westport, CT: Praeger Publishers, 1992).
286. Kritikos, M., ‘Traditional risk analysis and releases of GMOs into the European Union: space for non-scientific factors?’, European Law Review, 34 (2009), 405–32.
287. Kroner, B. K., Rosenberg, P. S., Aledort, L. M., Alvord, W. G. and Goedert, J. J., ‘HIV-1 infection incidence among persons with hemophilia in the United States and Europe’, Journal of Acquired Immune Deficiency Syndromes, 7 (1994), 279–86.
288. Kuhn, T. S., The Structure of scientific Revolutions, 3rd edn (University of Chicago Press, 1998).
289. Landzelius, K., ‘Introduction: Patient organization movements and new metamorphoses in patient hood’, Social Science and Medicine, 62 (2006), 529–37.
290. Lane, R., ‘Letter: Safety levels of blood for haemophiliacs’, The Independent, 15/4/91.
291. Laperche, S., Rouger, P., Smilovici, W., Herve, P. and Lefrere, J.-J., ‘Alternatives to nucleic acid testing in the blood transfusion service’, Lancet, 360 (2002), 1519.
292. Larkin, M., ‘WHO’s blood-safety initiative: a vain effort?’, Lancet, 355 (2000), 1245.
293. Laronche, M., ‘La Foundation national de transfusion sanguine justice ses comptes’, Le Monde, 8/06/91.
294. Latour, B., Science in Action: How to Follow Scientists and Engineers through Society(Cambridge, MA: Harvard University Press, 1987).
295. Lee, M., ‘Beyond safety? The broadening scope of risk regulation’, Current Legal Problems, 62 (2009), 242–85.
296. Le Grand, J., ‘Afterword’, in Oakley, A. and Ashton, J. (eds.), R. M. Titmuss, The Gift Relationship: From Human Blood to Social Policy(London: LSE Books, 1997), pp. 333–9.
297. Leiss, W., Tyshenko, M. and Krewski, D., ‘Men having sex with men donor deferral risk assessment: an analysis using risk management principles’, Transfusion Medicine Reviews, 22 (2008), 35–57.
298. Leveton, L., Sox, H. C. and Stoto, M. A. (eds.), HIV and the Blood Supply: An Analysis of Crisis Decision making(Committee to Study HIV Transmission through Blood and Blood Products, Division of Health Promotion and Disease Prevention) (Washington, DC: National Academy Press, 1995).
299. Levidow, L., ‘Biotechnology regulation as symbolic normalization’, Technology Analysis & Strategic Management, 6 (1994), 273–90.
300. Levi-Faur, D., ‘Foreword’, in Braithwaite, J., Regulatory Capitalism: How it Works, Ideas for Making it Work Better(Cheltenham: Edward Elgar Publishing, 2008), pp. vii–x.
301. Levy, J. A., Mitra, G. and Mozen, M. M., ‘Recovery and inactivation of infectious retroviruses from factor VIII concentration’, Lancet, ii (1984), 722–3.
302. Lewis, S., ‘EC Commission and blood self-sufficiency’, Lancet, 342 (1993), 1228.
303. Lindsay, A., Report of the Tribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters(Dublin: Government Publications, 2002).
304. Lodge, M., ‘Regulation, the regulatory state and European politics’, West European Politics, 31 (2009), 280–301.
305. Lofstedt, R. E. and Vogel, D., ‘The changing character of regulation: a comparison of Europe and the United States’, Risk Analysis, 21 (2001), 399–405.
306. Lucas, M., Transfusion sanguine et SIDA en 1985: chronologie des faits et de decisions pour ce qui concern les hémophiles(Paris: Inspections Générales des Affaires Sociales, 1991).
307. Maasen, S. and Weingart, P., ‘What’s new in scientific advice to politics?’, in Maasen, S. and Weingart, P. (eds.), Democratization of Expertise? Exploring Novel Forms of scientific Advice in Political Decision-Making – Sociology of the Sciences, 24 (2005), 1–19.
308. Magnette, J. P., ‘European governance and civic participation: beyond elitist citizenship?’, Political Studies, 51 (2003), 144–60.
309. Majone, G. (ed.), Regulating Europe(London: Routledge, 1996).
310. Majone, G., ‘Regulatory legitimacy’, in Majone, G. (ed)., Regulating Europe(London: Routledge, 1996), pp. 284–301.
311. Majone, G., ‘The rise of the regulatory state in Europe’, West European Politics, 17 (1994), 77–101.
312. Majone, G., ‘What price safety? The precautionary principle and its policy implications’, Journal of Common Market Studies, 40 (2002), 89–109.
313. Marshall, A.-M., ‘Injustice frames, legality and the everyday construction of sexual harassment’, Law and Social Inquiry, 28 (2003), 659–89.
314. Martin, L., ‘Aids scandal survivors demand new payout’, The Guardian, 16/4/06.
315. Martucci, J., ‘Negotiating exclusion: MSM, identity and blood policy in an age of AIDS’, Social Studies of Science, 40 (2010), 215–41.
316. Mather, L., ‘Theorizing about trial courts: lawyers, policymaking and tobacco litigation’, Law and Social Inquiry, 23 (1998), 897–940.
317. Mattli, W. and Woods, N., ‘In whose benefit? Explaining regulatory change in global politics’, in Mattli, W. and Woods, N. (eds.), The Politics of Global Regulation(Princeton University Press, 2009), pp. 1–43.
318. Mauss, M., The Gift: The Form and Reason for Exchange in Archaic Societies(London: Routledge, 1990), translated by W. D. Halls from M. Mauss, ‘Essai sur le don’, Sociologie et Anthropologie (Paris: Presses Universities de France, 1950).
319. McCann, M., Rights at Work: Pay Equity Reform and the Politics of Legal Mobilization(Chicago University Press, 1994).
320. McCarthy, M., ‘What’s going on at the World Health Organization?’, Lancet, 360 (2002), 1108–10.
321. McCullough, J., ‘Innovation in transfusion medicine and blood banking: documenting the record in 50 years of TRANSFUSION’, Transfusion, 50 (2010), 2542–6.
322. Medical Correspondent, ‘Blood victims need state relief fund of £ 2million a year’, The Guardian, 16/5/87.
323. Meikle, J., ‘Haemophiliacs demand £ 522m payout’, The Guardian, 19/06/02.
324. Miller, M. J., ‘Strict liability, negligence and the standard of care for transfusion-transmitted disease’, Arizona Law Review, 36 (1994), 473–513.
325. Mnookin, R. H. and Kornhauser, L., ‘Bargaining in the shadow of the law: the case of divorce’, Yale Law Journal, 88 (1979), 950–97.
326. Moran, M., ‘From command state to regulatory state’, Public Policy and Administration, 15 (2000), 1–13.
327. Moran, M., Governing the Health Care State: A Comparative Study of the United Kingdom, the United States and Germany(Manchester University Press, 1999).
328. Moran, M., The British Regulatory State: High Modernism and Hyper-Innovation(Oxford University Press, 2003).
329. Moran, M., ‘Understanding the regulatory state’, British Journal of Political Science, 32 (2002), 391–413.
330. Munzer, S., ‘An uneasy case against property rights in body parts’, Social Philosophy and Policy, 11 (1994), 259–86.
331. Murphy, M. F., Stanworth, S. J. and Yazer, M., ‘Transfusion practice and safety: current status and possibilities for improvement’, Vox Sanguinis, 100 (2011), 46–59.
332. Murray, T. H., ‘Gifts of the body and the needs of strangers’, Hastings Center Report, 17 (1987), 30–8.
333. National Health Service (NHS) Blood and Transplant, Current issues: deferral of men who have sex with men from blood donation: questions and answers: what are the donor selection criteria for men who have sex with men in other countries? (November 2011) (www.nhsbt.nhs.uk/current_issues/mhsm_faq/question_022.html).
334. National Health Service (NHS) Blood and Transplant, Exclusion of Men who have Sex with Men, Position Statement, 11 April 2011.
335. National Health Service (NHS) Blood and Transplant, Position Statement – November 2011: Deferral of men who have sex with men from blood donation (www.blood.co.uk/can-i-give-blood/exclusion).
336. National Hemophilia Foundation, Medical and scientific Advisory Council, Recommendations to Prevent AIDS in Patients with Hemophilia, 14 January 1983.
337. National Research Council, Risk Assessment in the Federal Government: Managing the Process(Washington, DC: National Academy Press, 1983).
338. Nau, J. -Y., ‘Entretien avec le president de l’Association des hémophiles’, Le Monde, 28/08/92.
339. Nau, J.-Y., ‘L’association française des h é mophiles réclame des indemnisations immédiates’, Le Monde, 16/09/91.
340. Nau, J.-Y. and Nouchi, F., ‘Affaire d’etat’, Le Monde, 16/09/91.
341. Nau, J.-Y. and Nouchi, F., ‘Des produits sanguins ont été importés illégalement’, Le Monde, 13/2/92.
342. Nau, J.-Y. and Nouchi, F., ‘La réforme du système de transfusion visera à garantir “la plus grande sécurité possible”’, Le Monde, 5/11/91.
343. Nauenberg, E. and Sullivan, S. D., ‘Firm behavior in the US market for Factor VIII: a need for policy?’, Social Science and Medicine, 39 (1994), 1591–603.
344. Nelkin, D., ‘Cultural perspectives on blood’, in Feldman, E. A. and Bayer, R. (eds.), Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster(New York: Oxford University Press, 1999), pp. 274–92.
345. Nouchi, F., ‘Vers un proc è s en assises de l’affaire du sang contaminé’, Le Monde, 22/05/99.
346. Nyugen, V., ‘Antiretroviral globalism: biopolitics and therapeutic citizenship’, in Ong, A. and Collier, S. (eds.), Global Assemblages: Technology, Politics and Ethics as Anthropological Problems(Malden, MA: Blackwell Publishing, 2005), pp. 124–44.
347. Oakley, A. and Ashton, J., ‘Introduction to the new edition’, in Oakley, A. and Ashton, J., (eds.), R. M. Titmuss, The Gift Relationship: From Human Blood to Social Policy(London: LSE Books, 1997), pp. 3–13.
348. Oakley, A. and Ashton, J. (eds.), R. M. Titmuss, The Gift Relationship: From Human Blood to Social Policy by Richard Titmuss(London: LSE Books, 1997).
349. Oakley, R. and Sherman, J., ‘Major pledges another £ 42million for haemophiliacs’, The Times, 12/12/90.
350. Ogus, A. I., Regulation: Legal Form and Economic Theory(Oxford: Hart Publishing, 2004).
351. O’Mahony, B. and Turner, A., ‘The Dublin Consensus Statement on vital issues relating to the collection of plasma and the manufacture of plasma products’, Vox Sanguinis, 98 (2010), 447–50.
352. O’Mahony, B. and Turner, A., ‘The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma-derived medicinal products’, Vox Sanguinis102 (2011) 140–3.
353. O’Malley, P., Risk, Uncertainty and Government(London: Glasshouse Press, 2004).
354. Organisation for Economic Co-operation and Development (OECD), The OECD Innovation Strategy: Getting a Head Start on Tomorrow(Paris: OECD, 2010).
355. Osborne, D. and Gaebler, T., Reinventing Government: How the Entrepreneurial Spirit Is Transforming the Public Sector(Reading, MA: Addison-Wesley, 1992).
356. Otway, H. and Winterfeldt, D., ‘Expert judgment in risk analysis and management: process, context and pitfalls’, Risk Analysis, 12 (1992), 83–93.
357. Penrod, J., ‘PPTA leadership interview: Gordon Naylor’, The Source(Spring 2009), 6–7.
358. Penrod, J. and Gustafson, M., ‘The evolution of safety in source plasma collection’, The Source(Spring 2009) 16–18.
359. Perkins, H. A. and Busch, M. P., ‘Transfusion-associated infections: 50 years of relentless challenges and remarkable progress’, Transfusion, 50 (2010), 2080–99.
360. Petryna, A., Life Exposed: Biological Citizens after Chernobyl(Princeton University Press, 2002).
361. Picciotto, S., ‘Introduction: reconceptualizing regulation in an era of globalization’, Journal of Law and Society, 29 (2005), 1–11.
362. Picciotto, S., Regulating Global Corporate Capitalism(Cambridge University Press, 2011).
363. Pierre, J. (ed.), Debating Governance: Authority, Steering and Democracy(Oxford University Press, 2000).
364. Pierre, J. and Peters, B. G., Governance, Politics and the State(Basingstoke: Palgrave Macmillan, 2000).
365. Pierson, P., ‘The limits of design: explaining institutional origins and change’, Governance, 13 (2000), 475–99.
366. Pieterse, M., ‘Health, social movements and rights-based litigation in South Africa’, Journal of Law and Society, 35 (2008), 364–88.
367. Pike, A., ‘Plea by the haemophiliacs who have AIDS’, Financial Times, 10/11/87.
368. Pillonel, J., Heraud-Bousquet, V., Pelletier, B., Semaille, C., Velter, A., Saura, C., Desenclos, J.-C., Dani, B. (and the blood donor epidemiological surveillance study group), ‘Deferral from donating blood of men who have sex with men: impact on the risk of HIV transmission by transfusion in France’, Vox Sanguinis102 (2011) 13–21.
369. Pinch, T., ‘The sun-set: the presentation of certainty in scientific life’, Social Studies of Science, 11 (1981), 131–58.
370. Plant, R., ‘Gifts, exchanges and the political economy of health care. Part 1: Should blood be bought and sold?’, Journal of Medical Ethics, 3 (1977), 166–73.
371. Plasma Protein Therapeutics Association (PPTA) (www. pptaglobal.org).
372. Plasma Protein Therapeutics Association (PPTA), PPTA Donor History Questionnaire(www.pptaglobal.org).
373. Plasma Protein Therapeutics Association (PPTA), Quality Standards of Excellence, Assurance and Leadership (QSEAL)(www.pptaglobal.org).
374. Plasma Protein Therapeutics Association (PPTA), The Facts about Plasma Collection(www.pptaglobal.org).
375. Plasma Protein Therapeutics Association (PPTA), The Facts about Plasma Used to Produce Life-Saving Therapies(www.pptaglobal.org).
376. Polletta, F. and Jasper, J., ‘Collective identity and social movements’, Annual Review of Sociology, 27 (2001), 283–305.
377. Preda, A., AIDS, Rhetoric and Medical Knowledge(Cambridge University Press, 2004).
378. Prosser, T., The Regulatory Enterprise: Government, Regulation and Legitimacy(Oxford University Press, 2010).
379. Quigley, M., ‘A NICE fallacy’, Journal of Medical Ethics, 33 (2007), 465–6.
380. Rabinow, P., French DNA – Trouble in Purgatory(Chicago University Press, 1999).
381. Radin, M., Contested Commodities: The Trouble with Trade in Sex, Children, Body Parts and Other Things(Cambridge, MA: Harvard University Press, 1996).
382. Radin, P., ‘“To me, it’s my life”: medical communication, trust and activism in cyberspace’, Social Science and Medicine, 62 (2006), 591–601.
383. Raffensperger, C. and Tickner, J. (eds.), Protecting Public Health and the Environment: Implementing the Precautionary Principle(Washington, DC: Island Press, 1999).
384. Rautonen, J., ‘Finland: national policy’, Pharmaceuticals Policy and Law, 7 (2006), 221–4.
385. Renn, O., ‘Three decades of risk research: accomplishments and new challenges’, Journal of Risk Research, 1 (1998), 49–71.
386. Resnik, S., Blood Saga: Hemophilia, AIDS and the Survival of a Community(Berkeley, CA: University of California Press, 1999).
387. Rio Declaration on Environment and Development (1992) (www.unep.org/Documents.Multi lingual/Default.asp?documentid=78&articleid=1163).
388. Rizza, C. R., Spooner, R. J. D., Giangrande, P. (on behalf of the UK Haemophilia Centre Doctors’ Organisation), ‘Treatment of haemophilia in the UK: 1981–1996’, Haemophilia, 7 (2001), 349–59.
389. Roberts, D. J., Allain, J.-P., Kitchen, A. D., Field, S. and Bates, I., ‘Blood transfusion in a global context’, in Murphy, M. F. and Pamphilon, D. H. (eds.), Practical Transfusion Medicine, 3rd edn (Oxford: Wiley-Blackwell, 2009), pp. 251–65.
390. Robinson, E. A. E., ‘The European Union Blood Safety Directive and its implications for blood services’, Vox Sanguinis, 93 (2007), 122–30.
391. Roehr, B., ‘Should men who have ever had sex with men be allowed to give blood? Yes’, British Medical Journal, 338 (2009), b311.
392. Rose, N. and Novas, C., ‘Biological citizenship’, in Ong, A. and Collier, S. (eds.), Global Assemblages: Technology, Politics and Ethics as Anthropological Problems(Malden, MA: Blackwell Publishing, 2005), pp. 439–63.
393. Rosenau, J. N., ‘Governance in a new global order’, in Held, D. and McGrew, A. (eds.), Governing Globalization: Power, Authority and Global Governance(Cambridge: Polity Press, 2002), pp. 70–86.
394. Roth, W. K., ‘Quarantine plasma: quo vadis?’ Transfusion Medicine and Hemotherapy, 37 (2010), 118–22.
395. Rothstein, H., Huber, M. and Gaskell, G., ‘A theory of risk colonization: the spiralling regulatory logics of institutional and societal risk’, Economy and Society, 35 (2006), 91–112.
396. Rouger, P., ‘France: national policy’, Pharmaceuticals Policy and Law, 7 (2006), 255–9.
397. Rueda, A., ‘Rethinking blood shield statutes in view of the hepatitis C pandemic and other emerging threats to the blood supply’, Journal of Health Law, 34 (2001), 419–58.
398. Russo, D. J., ‘Blood bank liability to recipients of HIV contaminated blood’, University of Dayton Law Review, 87 (1992–1993), 87–107.
399. Sabatier, P. A., ‘The advocacy coalition framework: revisions and relevance for Europe’, Journal of European Public Policy, 5 (1998), 98–130.
400. SaBTO (Advisory Committee on the Safety of Blood, Tissues and Organs), Donor Selection Criteria Review (April 2011) (www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_129796?ssSourceSiteId=ab).
401. SaBTO (Advisory Committee on the Safety of Blood, Tissues and Organs), Evidence-base for the exclusion of potential donors due to sexual behaviours associated with an increased risk of transfusion-transmissible infections – a report to the Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO), SaBTO 9–27 January 2009, Agenda Item 5 (www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_111629.pdf)
402. SaBTO (Advisory Committee on the Safety of Blood, Tissues and Organs), Summary of the Fourteenth Meeting, 3 May 2011 (www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_129855.pdf)
403. Sanchez, A. M., Schreiber, G. B., Nass, C. C., Glynn, S., Kessler, D., Hirschler, N., Fridey, J., Bethel, J., Murphy, E. and Busch, M. P., ‘The impact of male to male sexual experience on risk profiles of blood donors’, Transfusion, 45 (2005), 404–13.
404. Sapolsky, H. M. and Finkelstein, S. N., ‘Blood policy revisited: a new look at the “gift relationship”’, Public Interest, 46 (1977), 15–27.
405. Saul, J., The Tainted Gift: A Comparative Study of the Culture and Politics of the Contamination of the Blood Supply with the AIDS Virus in France and the United States(Cornell University, unpublished PhD thesis, 2005).
406. Scharpf, F., Governing in Europe: Effective and Democratic?(Oxford University Press, 1999).
407. Schneider, D. M., ‘What is kinship all about?’, in Parkin, R. and Stone, L. (eds.), Kinship and Family: An Anthropological Reader(Oxford: Blackwell Publishing, 2003), pp. 257–74.
408. Schneider, W. H., ‘Arnault Tzanck, MD (1886–1954)’, Transfusion Medicine Reviews, 24 (2010), 147–50.
409. Scott, C., ‘Governing without law or governing without government? New-ish governance and legitimacy of the EU’, European Law Journal, 15 (2009), 160–73.
410. Scott, C., ‘Regulation in the age of governance: the rise of the post-regulatory state’, in Jordana, J. and Levi-Faur, D. (eds.), The Politics of Regulation: Institutions and Regulatory Reforms for the Age of Governance(Cheltenham: Edward Elgar, 2004), pp. 145–74.
411. Seed, C., Kiely, P., Law, M. and Keller, A. J., ‘No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men’, Transfusion, 50 (2010), 2722–30.
412. Setbon, M., Pouvoirs contre sida: de la transfusion sanguine au dépistage: decisions et pratiques en France, Grande-Bretagne et Suède(Paris: Éditions du Seuil, 1993).
413. Shaz, B. H. and Hillyer, C. D., ‘Transfusion medicine as a profession: evolution over the past 50 years’, Transfusion, 50 (2010), 2536–41.
414. Sherman, J., ‘AIDS payment call for haemophiliacs’, The Times, 13/4/87.
415. Shilts, R., And the Band Played On: Politics, People and the AIDS Epidemic(New York: Penguin Books, 1987).
416. Shu-Acquaye, F. and Innet, L., ‘Human blood and its transfusion: the twists and turns of legal thinking’, Quinnipiac Health Law Journal, 9 (2005–2006), 33–67.
417. Silvester, G., ‘Regulatory overview – stable products background, current state of the art and future challenges’, Pharmaceuticals Policy and Law, 7 (2006), 151–69.
418. Singer, P., ‘Altruism and commerce: a defence of Titmuss against Arrow’, Philosophy and Public Affairs, 2 (1973), 312–20.
419. Siplon, P., AIDS and the Policy Struggle in the United States(Washington, DC: Georgetown University Press, 2002).
420. Siplon, P. and Hoag, B., ‘Protection for whom? Blood policy creation and interest representation’, Policy Studies Review, 18 (2001), 193–224.
421. Skelcher, C. and Torfing, J., ‘Improving democratic governance through institutional design: civic participation and democratic ownership in Europe’, Regulation & Governance, 4 (2010), 71–91.
422. Skogstad, G., ‘Legitimacy and/or policy effectiveness?: Network governance and GMO regulation in the European Union’, Journal of European Public Policy, 10 (2003), 321–38.
423. Slovic, P., ‘Perceived risk, trust, and democracy’, Risk Analysis, 13 (1993), 675–82.
424. Smith, M. J., ‘Mad cows and mad money: problems of risk in the marking and understanding of policy’, British Journal of Politics and International Relations, 6 (2004), 312–32.
425. Smith, M. J., The Core Executive in Britain(Basingstoke: Macmillan, 1999).
426. Smith, R., ‘Doctors question whether all blood transfusions are effective and necessary’, British Medical Journal, 330 (2005), 558.
427. Snow, D. A., Rochford, E. B., Worden, S. K. and Benford, R. D., ‘Frame alignment processes, micromobilization and movement participation’, American Sociological Review, 51 (1986), 464–81.
428. Soldan, K. and Sinka, K., ‘Evaluation of the de-selection of men who have had sex with men from blood donation in England’, Vox Sanguinis, 84 (2003), 265–73.
429. Soulier, J.-P., Transfusion et sida: le droit à la verité(Paris: É ditions Frison-Roche, 1992).
430. Stainsby, D., Jones, H., Asher, D., Atterbury, C., Boncinelli, A., Brant, L., Chapman, C. E., Davison, K., Gerrard, R., Gray, A., Knowles, S., Love, E. M., Milkins, C., McClelland, D. B., Norfolk, D. R., Soldan, K., Taylor, C., Revill, J., Williamson, L. M. and Cohen, H. (SHOT Steering Group), ‘Serious hazards of transfusion: a decade of haemovigilance in the UK’, Transfusion Medicine Reviews, 20 (2006), 273–82.
431. Starr, D., Blood: An Epic History of Medicine and Commerce(New York: Alfred A. Knopf, 1998).
432. Starr, D., ‘Medicine, money, and myth: an epic history of blood’, Transfusion Medicine, 11 (2001), 119–21.
433. Steele, J., Risks and Legal Theory(Oxford: Hart Publishing, 2004).
434. Steffen, M., ‘The nation’s blood: medicine, justice and the state’, in Feldman, E. A. and Bayer, R. (eds.), Blood Feuds: AIDS, Blood and the Politics of Medical Disaster(New York: Oxford University Press, 1999), pp. 95–126.
435. Stein, J., Besley, J., Brook, C., Hamill, M., Klein, E., Krewski, D., Murphy, G., Richardson, M., Sirna, J., Skinner, M., Steiner, R., van Aken, P. and Devine, D., ‘Risk-based decision-making for blood safety: preliminary report of a consensus conference’, Vox Sanguinis(2011), doi: 10.111.j.1423-0410.2011.01526.x.
436. Stoker, G., ‘Designing institutions for governance in complex environments: normative, rational choice and cultural institutional theories explored and contrasted’, ESRC Fellowship Paper No. 1(University of Manchester, 2004).
437. Stoto, M. A., ‘The precautionary principle and emerging biological risks: lessons from swine l u and HIV in blood products’, Public Health Reports, 117 (2002), 546–52.
438. Strong, M., Farrugia, A. and Rebulla, P., ‘Stem cell and cellular therapy developments’, Biologicals, 27 (2009), 103–7.
439. Sullivan, P., ‘Developing an administrative plan for transfusion medicine – a global perspective’, Transfusion, 45 (2005), 224S–40S.
440. Sunstein, C., Laws of Fear: Beyond the Precautionary Principle(Cambridge University Press, 2005).
441. Syrett, K., ‘Nice work? Rationing, review and the “legitimacy problem” in the new NHS’, Medical Law Review, 10 (2002), 1–27.
442. Tabor, E., ‘The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1’, Transfusion, 39 (1999), 1160–8.
443. Terrence Higgins Trust, Blood donations regulations changes – THT’s response and guide (www.tht.org.uk/informationresources/policy/healthpolicy/blooddonations).
444. The Contaminated Blood (Support for Infected and Bereaved Persons) Bill [HL] 2009–10.
445. Thelen, K. and Steinmo, S., ‘Historical institutionalism in comparative politics’, in Steinmo, S., Thelen, K. and Longstreth, F. (eds.), Structuring Politics: Historical Institutionalism in Comparative Perspective (Cambridge University Press, 1992), pp. 1–32.
446. Thomassen, J. and Schmitt, H., ‘Democracy and legitimacy in the European Union’ (2004) (www.mzes.unimannheim.de/publications/papers/Schmitt_26_1_04.pdf).
447. Titmuss, R. M., The Gift Relationship: From Human Blood to Social Policy(London: George Allen & Unwin, 1970).
448. Travis, A. and Dyer, C., ‘Government offers extra £ 42 million to blood victims’, The Guardian, 12/12/90.
449. Tutton, R., ‘Gift relationships in genetics research’, Science as Culture, 11 (2002), 524–42.
450. UK Haemophilia Centre Doctors’ Organisation (UKHCDO) (AIDS Group), ‘Prevalence of HIV antibody to HTLV-III in haemophiliacs in the UK’, British Medical Journal, 293 (19/7/86), 175–6.
451. Unknown author, ‘Class actions. Class certification of mass torts. Seventh circuit overturns rule 23(b) certification of a plaintiff class of haemophiliacs. In re Rhone-Poulenc Rorer Inc., 51 F.3d 1293 (7th Circ), Cert Denied, 116 S. Ct. 1984 (1995)’, Harvard Law Review, 109 (1996), 870–5.
452. Unknown author, ‘Le professeur Jacques Roux et les docteurs Robert Netter et Michel Garetta ontété inculpés’, Le Monde, 23/10/91.
453. Unknown author, ‘Of cash and care and simple sense’, The Guardian, 2/12/90.
454. US Department of Health and Human Services, Advisory Committee on Blood Safety and Availability, Recommendations (www.hhs.gov/ash/bloodsafety/advisorycommittee/recommendations/resolutions.html).
455. Valverde, J. L., ‘The political dimension of blood and plasma derivatives’, Pharmaceuticals Policy and Law, 7 (2006), 21–33.
456. Vamvakas, E. C., ‘Evidence-based practice of transfusion medicine: is it possible and what do the words mean?’ Transfusion Medicine Reviews, 18 (2004), 267–78.
457. Vamvakas, E. C., ‘Relative risk of reducing the lifetime blood donation deferral for men who have had sex with men versus currently tolerated transfusion risks’, Transfusion Medicine Reviews, 25 (2011), 47–60.
458. Vamvakas, E. C., ‘Scientii c background on the risk engendered by reducing the lifetime blood donation deferral period for men who have sex with men’, Transfusion Medicine Reviews, 23 (2009), 85–102.
459. van der Poel, C. L., Seifried, E. and Schaasberg, W. P., ‘Paying for blood donations: still a risk?’, Vox Sanguinis, 83 (2002), 285–93.
460. Various authors, ‘Sang: Fabius et Dufoix relaxés, Hervé condamné’, Le Monde, 10/03/99.
461. Vincent-Jones, P., ‘Embedding economic relationships through social learning? The limits of patient and public involvement in healthcare governance in England’, Journal of Law and Society, 38 (2011), 215–44.
462. Voak, D., Caffrey, E. A., Barbara, J. A. J., Pollock, A., Scott, M. and Contreras, M. C., ‘Affordable safety for the blood supply in developed and developing countries’, Transfusion Medicine, 8 (1998), 73–6.
463. Vogel, D., ‘The globalization of pharmaceutical regulation’, Governance: An International Journal of Policy and Administration, 11 (1998), 1–22.
464. Vogel, D., ‘The hare and the tortoise revisited: the new politics of consumer and environmental regulation in Europe’, British Journal of Political Science, 33 (2003), 557–80.
465. von Auer, F., ‘Germany: national policy’, Pharmaceuticals Policy and Law, 7 (2006), 225–31.
466. von Hoegen, I., ‘Epidemiology regulatory landscape’, The Source(Fall 2011), 22–3.
467. von Hoegen, I. and Gustafson, M., ‘The importance of greater regulatory harmonization’, Pharmaceuticals Policy and Law, 7 (2006), 171–6.
468. von Schubert, H., ‘Donated blood – gift or commodity? Some economic and ethical considerations on voluntary vs commercial donation of blood’, Social Science and Medicine, 39 (1994), 201–6.
469. Voo, T. C., ‘The social rationale of the gift relationship’, Journal of Medical Ethics27 (2011) 663–7.
470. Vos, E., ‘EU food safety regulation in the aftermath of the BSE crisis’, Journal of Consumer Policy, 23 (2000), 227–55.
471. Vos, E., ‘Overcoming the crisis of confidence: risk regulation in an enlarged European Union’, Inaugural Lecture, University of Maastricht (2004), 1–27.
472. Waldby, C. and Mitchell, R., Tissue Economies: Blood, Organs, and Cell Lines in Late Capitalism(Durham, NC: Duke University Press, 2006).
473. Waldby, C., Rosengarten, M., Treloar, C. and Fraser, S., ‘Blood and bio identity: ideas about self, boundaries and risk among blood donors and people living with Hepatitis C’, Social Science and Medicine, 59 (2004), 1461–71.
474. Waller, C., ‘Historical perspectives on blood and plasma products, the stakeholders and the issues’, Pharmaceuticals Policy and Law, 7 (2006), 7–19.
475. Webster, A., Health, Technology and Society: A Critique(Houndmills: Palgrave Macmillan, 2007).
476. Webster, A. (ed.), New Technologies in Health Care: Challenge, Change and Innovation(Houndmills: Palgrave Macmillan, 2006).
477. Weimer, M., ‘Applying precaution in EU authorization of genetically modified products – challenges and suggestions for reform’, European Law Journal, 16 (2010), 624–57.
478. Weingart, P., ‘scientific expertise and political accountability: paradoxes of science in politics’, Science and Public Policy, 26 (1999), 151–61.
479. Westfall, P. T., ‘Hepatitis, AIDS and the blood product exemption from strict products liability in California: a reassessment’, Hastings Law Journal, 37 (1986), 1101–32.
480. Wiener, J. B. and Rogers, M., ‘Comparing precaution in the United States and Europe’, Journal of Risk Research, 5 (2002), 317–49.
481. Williams, G., ‘The genesis of chronic illness’, Sociology of Health and Illness, 6 (1984), 175–200.
482. Williamson, C., ‘The patient movement as an emancipation movement’, Health Expectations, 11 (2008), 102–12.
483. Wilson, K., ‘A framework for applying the precautionary principle to transfusion safety’, Transfusion Medicine Reviews, 25 (2011), 177–83.
484. Wilson, K. and Ricketts, M. N., ‘The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease’, Transfusion, 44 (2004), 1475–8.
485. Wilson, K., Wilson, M., Hébert, P. C. and Graham, I., ‘The application of the precautionary principle to the blood system: the Canadian blood system’s vCJD donor deferral policy’, Transfusion Medicine Reviews, 17 (2003), 89–94.
486. Wingspread Consensus Statement on the Precautionary Principle (1998) (www.sehn.org/wing.html).
487. World Federation of Hemophilia (WFH) (www.wfh.org).
488. World Health Organization (WHO), Blood Products and Related Biologicals, Blood Regulators Network (www.who.int/bloodproducts/brn/en).
489. World Health Organization (WHO), Blood Transfusion Safety, Collaboration and Partnerships (www.who.int/bloodsafety/collaboration/en/index.html).
490. World Health Organization (WHO), Blood Transfusion Safety, Global Collaboration for Blood Safety (2000–2010) (www.who.int/bloodsafety/gcbs/en).
491. World Health Organization (WHO), Blood Transfusion Safety, Global Database on Blood Safety (www.who.int/bloodsafety/global_database/en).
492. World Health Organization (WHO), Expert Committee on Biological Standardization (www.who.int/biologicals/expert_committee/en/index.html).
493. World Health Organization (WHO), Expert Committee on Biological Standardization. Recommendations for the production, control and regulation of human plasma for fractionation (Technical Report Series – 941, Annex 4, 2006).
494. World Health Organization, Global Blood Safety and Availability: Key Facts and Figures, 2010(www.who.int/worldblooddonorday/media/en).
495. World Health Organization (WHO), Global Consultation, 100% Voluntary Non-Remunerated Donation of Blood and Blood Components(Geneva: WHO, 2009).
496. World Health Organization (WHO), The Melbourne Declaration on 100% Voluntary Non-remunerated Donation of Blood and Blood Components (June 2009) (www.who.int).
497. Wynne, B., ‘Creating public alienation: expert cultures of risk and ethics on GMOs’, Science as Culture, 10 (2001), 445–81.
498. Wynne, B., ‘May the sheep safely graze? A reflexive view of the expert-lay knowledge divide’, in Lash, S., Szerszynski, B. and Wynne, B. (eds.), Risk, Environment and Modernity: Towards a New Ecology(London: Sage, 1996), pp. 44–83.
499. Wynne, B., ‘Risk and social learning: reification to engagement’, in Krimsky, S. and Golding, D. (eds.), Social Theories of Risk(Westport, CT: Praeger Publishers, 1992), pp. 275–300.
500. Wynne, B., ‘Uncertainty and environmental learning: reconceiving science and policy in the preventative paradigm’, Global Environmental Change, 2 (1992), 111–27.
501. Yeung, K., ‘The regulatory state’, in Baldwin, R., Cave, M. and Lodge, M. (eds.), The Oxford Handbook of Regulation(Oxford University Press, 2010), pp. 64–83.